← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleAmgenPhase 3

Romosozumab (Romosozumab)

Postmenopausal Osteoporosis · Postmenopausal Osteoporosis

#PostmenopausalOsteoporosis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Rucaparib and Nivolumab)

Small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 4%임상시험 1상태 ACTIVE
AntibodystaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#항체#면역항체+4
효능 ORR 41%임상시험 1상태 ACTIVE
AntibodystaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#항체#면역항체+2
효능 ORR 66.7%임상시험 1상태 DISCONTINUED
AntibodystaleSamsung Bioepis Co., Ltd.Phase 3

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

proposed trastuzumab biosimilar (SB3, SB3 (proposed trastuzumab biosimilar))

Breast Neoplasms · HER2

#HER2#Antibody#Preclinical#항체#면역항체+3
효능 ORR 91.2%임상시험 1상태 DISCONTINUED
AntibodystaleSamsung Bioepis Co., Ltd.Approved

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Approved#항체#면역항체+2
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 3

proposed biosimilar to adalimumab (SB5, SB5 (proposed biosimilar to adalimumab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInstitut Cancerologie de l'OuestPhase 2

durvalumab (Imfinzi, SBRT + Durvalumab)

Node; Prostate; Bone Metastases · Node; Prostate

#NodeProstate#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleAbramson Cancer Center at Penn …Phase 1

atezolizumab (Tecentriq, SBRT + atezolizumab and bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

SC0191 + Bevacizumab (SC0191 + Bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenApproved

daratumumab (Darzalex, SCT800 and Daratumumab)

Hemophilia A With Inhibitor · Hemophilia A With Inhibitor

#HemophiliaAWithInhibitor#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-huCD40 mAb (SGN-40, SGN-40 (anti-huCD40 mAb))

Leukemia, Lymphocytic, Chronic · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleHenan Cancer HospitalPhase 2

trastuzumab (Herceptin, SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

SIACI of cetuximab and bevacizumab (SIACI of cetuximab and bevacizumab)

Glioblastoma Multiforme; Anaplastic Astrocytoma · Glioblastoma Multiforme

#GlioblastomaMultiforme#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

Sarilumab + Cemiplimab + Paclitaxel (Sarilumab + Cemiplimab + Paclitaxel)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleHuashan HospitalPreclinical

Satralizumab (Satralizumab)

Neuromyelitis Optica Spectrum Disorders (NMOSD) · Neuromyelitis Optica Spectrum Disorders

#NeuromyelitisOpticaSpectrumDisor#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE

47 / 62 페이지

← 이전다음 →